No pharmacologic treatment has received regulatory approval for borderline personality disorder, in the United States or elsewhere. According to a 2010 Cochrane systematic review, 27 randomized clinical trials of pharmacologic agents had been conducted in borderline personality disorder up to 2008 (1). In the past 5 years, most such trials have focused on mood stabilizers and second-generation antipsychotics. Among the second-generation antipsychotics, there has been one study with positive findings for aripiprazole (2), one study with negative findings for ziprasidone (3), and three studies with mixed results for olanzapine (4-6). Studies have suggested efficacy for several anticonvulsants, including valproate, lamotrigine, and topiramate (1). There have also been a number of negative studies for antidepressants, including fluoxetine, fluvoxamine, mianserin, and phenelzine (1).
展开▼
